Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Zentalis Pharmaceuticals announced that two abstracts for its lead asset azenosertib have been accepted for presentation at the ESMO Congress 2026 in Madrid. A rapid oral presentation will highlight overall survival data from the DENALI Part 1b study, showcasing long-term survival benefits in patients with Cyclin E1-positive platinum-resistant ovarian cancer.
Key figures
- Drug Name
- azenosertib
- Phase Of Trial
- Phase 2 and Phase 3
- Optimal dose
- 400mg QD 5:2
- Enrollment aspenova
- approximately 420
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.